Objective: To assess the public health impact of different antiviral therapies (AVT) for chronic hepatitis C (CHC) when accounting for CHC-related diseases (e.g., HIV/HCV co-infection, haemophilia, history of i.v. drug use). Methods: Design: We used a Markov model, the German Hepatitis C Model (GEHMO) [1], combined with with prevalence and incidence cohort simulation. Data Sources: Pooled efficacy data from clinical trials and literature-based epidemiologic data on CHC and co-morbidities. Target Population: All treatable treatment-naïve German patients with known CHC and elevated ALT levels. Time Horizon: 20 years. Interventions: Initial AVT with peginterferon plus ribavirin (Peg+R), interferon plus ribavirin (IFN+R), interferon monotherapy (IFN), and no AVT (NoAVT). Results: After excluding patients with normal ALT, non-adherence, contraindications, current substance abuse, and previous treatment, 43,000 prevalent cases (11%) and 1,400 incident cases/year (22%) remained in the decision model. Without AVT, the model predicts 20-year cumulative incidences of 29,000 patients with compensated cirrhosis, 16,000 with decompensated cirrhosis, 300 with hepatocellular carcinoma, 1,200 with need for liver transplant, and 16,000 CHC-related deaths. Peg+R can reduce each of these numbers by 47–58% (29–37% for IFN+R, 12–15% for INF). During 20 years, Peg+R saves 53,000 life years or 49,000 QALY. Conclusions: Due to decreasing CHC incidence absolute numbers of patients with compensated cirrhosis are already declining. However, the number of hepatocellular carcinoma, CHC-related deaths, and need for liver transplants is expected to increase for 20 years or more. About half of the morbidity and mortality can be eliminated by treatment with peginterferon and ribavirin. Grant Support: German Federal Ministry of Health and Social Security and German Hepatitis C Coalition [1] Siebert U, Sroczynski G, unter Mitwirkung der German Hepatitis C Model (GEHMO) Group und des HTA-Expertenpanels für Hepatitis C. Antivirale Therapie bei Patienten mit chronischer Hepatitis C in Deutschland. Medizinische und ökonomische Evaluation der initialen Kombinationstherapie mit Interferon / Peginterferon und Ribavirin. Health Technology Assessment Vol 8. Schriftenreihe des DIMDI im Auftrag des Bundesministeriums für Gesundheit und Soziale Sicherung. Köln: DIMDI, 2003; 202 S.